Search

PTC Therapeutics Inc

Lezárt

SzektorEgészségügy

72.75 3.47

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

67.72

Maximum

71.37

Fő mutatók

By Trading Economics

Bevétel

86M

83M

Értékesítés

88M

361M

P/E

Szektor átlag

7.597

57.371

Egy részvényre jutó nyereség

0.92

Profit margin

23.16

Munkavállalók

991

EBITDA

198M

162M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+41.92% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 3.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-205M

6.1B

Előző nyitás

69.28

Előző zárás

72.75

Hangulat hírek alapján

By Acuity

54%

46%

276 / 340 Rangsor szerint Healthcare

PTC Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 21. 19:26 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid a broader market rebound in safe-haven assets.

2026. aug. 20. 20:02 UTC

PTC Therapeutics shares are lower amid significant downward pressure on biotechnology stocks. The stock remains below its 20-day moving average.

2026. aug. 19. 19:46 UTC

News

PTC Therapeutics is acquiring the ST-920 gene therapy asset for $111 million, including potential milestone payments, as shares trade higher since Tuesday's close.

2026. aug. 18. 19:36 UTC

PTC Therapeutics Inc shares are lower amid cautious market sentiment influenced by rising treasury yields and inflation concerns. No specific news was identified for the decline.

2026. aug. 14. 19:46 UTC

PTC Therapeutics shares are lower, reflecting broader market sentiment after U.S. retail sales unexpectedly declined in July. The stock is below its 20-day moving average.

2026. aug. 13. 19:36 UTC

News
Social Media

PTC Therapeutics announced the acquisition of ST-920 for $111 million. Shares are lower amid ongoing bearish trends, despite Wells Fargo's Overweight rating and $109 price target.

2026. aug. 12. 23:51 UTC

Social Media
News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

2026. aug. 11. 19:46 UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.

2026. aug. 10. 19:46 UTC

PTC Therapeutics shares are higher today amid broader market uncertainty regarding the Federal Reserve's interest rate policy following last week's employment report.

2026. aug. 7. 21:02 UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

2026. aug. 6. 19:56 UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

2026. aug. 5. 19:26 UTC

News

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

2026. aug. 4. 20:07 UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

2026. aug. 3. 19:46 UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

2026. júl. 31. 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

2026. júl. 30. 22:31 UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

2026. júl. 29. 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

2026. júl. 28. 18:31 UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

2026. júl. 27. 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

2026. júl. 22. 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

2026. júl. 21. 18:01 UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

2026. júl. 20. 19:56 UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Társak összehasonlítása

Árváltozás

PTC Therapeutics Inc Előrejelzés

Célár

By TipRanks

41.92% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 99.09 USD  41.92%

Magas 130 USD

Alacsony 70 USD

11 Wall Street elemző 12 hónapos célárain alapulva a(z)PTC Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

11 ratings

9

Vétel

1

Tartás

1

Eladás

Hangulat

By Acuity

276 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat